Alpha 2.0
Login Register
» Articles » PMID: 38762525

Direct Comparison of SARS-CoV-2 Variant Specific Neutralizing Antibodies in Human and Hamster Sera

Overview
Journal NPJ Vaccines
Date 2024 May 18
PMID 38762525
Authors
Annika Rossler
Antonia Netzl
Ludwig Knabl
Samuel H Wilks
Barbara Muhlemann
Sina Tureli
Anna Mykytyn
Dorothee von Laer
Bart L Haagmans
Derek J Smith
Janine Kimpel
Affiliations
Soon will be listed here.
Abstract

Antigenic characterization of newly emerging SARS-CoV-2 variants is important to assess their immune escape and judge the need for future vaccine updates. To bridge data obtained from animal sera with human sera, we analyzed neutralizing antibody titers in human and hamster single infection sera in a highly controlled setting using the same authentic virus neutralization assay performed in one laboratory. Using a Bayesian framework, we found that titer fold changes in hamster sera corresponded well to human sera and that hamster sera generally exhibited higher reactivity.

Citing Articles

Nonhuman primate antigenic cartography of SARS-CoV-2.

Rossler A, Netzl A, Lasrado N, Chaudhari J, Muhlemann B, Wilks S Cell Rep. 2025; 44(1):115140.

PMID: 39754717 PMC: 11781863. DOI: 10.1016/j.celrep.2024.115140.

Human and hamster sera correlate well in identifying antigenic drift among SARS-CoV-2 variants, including JN.1.

Wang W, Bhushan G, Paz S, Stauft C, Selvaraj P, Goguet E J Virol. 2024; 98(11):e0094824.

PMID: 39365051 PMC: 11578088. DOI: 10.1128/jvi.00948-24.

Antigenic cartography using variant-specific hamster sera reveals substantial antigenic variation among Omicron subvariants.

Muhlemann B, Trimpert J, Walper F, Schmidt M, Jansen J, Schroeder S Proc Natl Acad Sci U S A. 2024; 121(32):e2310917121.

PMID: 39078681 PMC: 11317614. DOI: 10.1073/pnas.2310917121.

References
1.
Smith D, Lapedes A, de Jong J, Bestebroer T, Rimmelzwaan G, Osterhaus A . Mapping the antigenic and genetic evolution of influenza virus. Science. 2004; 305(5682):371-6. DOI: 10.1126/science.1097211. View
2.
Wilks S, Muhlemann B, Shen X, Tureli S, LeGresley E, Netzl A . Mapping SARS-CoV-2 antigenic relationships and serological responses. Science. 2023; 382(6666):eadj0070. DOI: 10.1126/science.adj0070. View
3.
Mykytyn A, Rosu M, Kok A, Rissmann M, van Amerongen G, GeurtsvanKessel C . Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1, BQ.1.1, and XBB.1. Lancet Microbe. 2023; 4(5):e294-e295. PMC: 9842387. DOI: 10.1016/S2666-5247(22)00384-6. View
4.
DeGrace M, Ghedin E, Frieman M, Krammer F, Grifoni A, Alisoltani A . Defining the risk of SARS-CoV-2 variants on immune protection. Nature. 2022; 605(7911):640-652. PMC: 9345323. DOI: 10.1038/s41586-022-04690-5. View
5.
Yang S, Yu Y, Jian F, Song W, Yisimayi A, Chen X . Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86. Lancet Infect Dis. 2023; 23(11):e457-e459. DOI: 10.1016/S1473-3099(23)00573-X. View